Antiviral agents are commonly used for cytomegalovirus (CMV) prophylaxis or therapy after
solid organ transplantation. Until recently, the detection of drug‐resistant CMV in this setting …

Background The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance
was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for …

We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations
in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days …

Despite advances in the prophylaxis and acute treatment of cytomegalovirus (CMV), it
remains an important pathogen affecting the short-and long-term clinical outcome of solid …

Transplant recipients that have not been previously exposed to the cytomegalovirus (CMV)
are highly susceptible to viral diseases while under immunosuppression therapy. CMV …

Objectives Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the
transplant setting. No longitudinal cohort studies of CMV resistance in a real-life setting have …

In the era of more aggressive immunosuppressive regimens and antiviral prophylaxis,
ganciclovir-resistant cytomegalovirus (CMV) has been recognized as an important clinical …

Cytomegalovirus (CMV) is a significant human pathogen, especially for
immunocompromised patients, often treated with one or more antiviral drugs. Although the …

Background: Valganciclovir prophylaxis is reportedly associated with a low incidence of
ganciclovir‐resistant cytomegalovirus (CMV). We assessed the incidence, clinical features …

JM Iwasenko, GM Scott, Z. Naing, AR Glanville, WD Rawlinson. Diversity of antiviral‐
resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis …